BIO Calls For Incentives In Novel Non-Addictive Pain Medicine Space

The Biotechnology Innovation Organization (BIO) in a newly released report found that development of and investment in novel pain medicines has been sorely lacking over the past decade, with only two novel chemical entities -- those with no prior approval history -- entering the market since 2007. In the report, released Sunday (Feb. 11), BIO argues that innovation should be incentivized, and investors need to be reassured that payers will pay for innovative medicines and not just push for generics...